Other equities analysts have also issued research reports about the company. Leerink Partnrs upgraded Voyager Therapeutics to a "strong-buy" rating in a research note on Wednesday, October 16th. Leerink Partners began coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They issued an "outperform" rating and a $15.00 price target for the company. Wedbush cut their price objective on Voyager Therapeutics from $8.00 to $7.00 and set a "neutral" rating for the company in a research note on Wednesday, August 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research note on Thursday. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Voyager Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $17.43.
Get Our Latest Report on VYGR
Shares of Voyager Therapeutics stock traded up $0.17 on Friday, hitting $6.75. The company's stock had a trading volume of 469,161 shares, compared to its average volume of 645,261. Voyager Therapeutics has a 1 year low of $5.71 and a 1 year high of $11.72. The firm has a fifty day moving average price of $6.55 and a 200-day moving average price of $7.63. The company has a market capitalization of $367.16 million, a price-to-earnings ratio of -135.00 and a beta of 0.91.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The firm had revenue of $29.58 million during the quarter, compared to analyst estimates of $11.52 million. During the same quarter in the previous year, the business earned ($0.51) EPS. As a group, analysts forecast that Voyager Therapeutics will post -1.27 EPS for the current year.
In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.53% of the company's stock.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company's stock valued at $30,087,000 after acquiring an additional 702,030 shares during the last quarter. Great Point Partners LLC acquired a new position in Voyager Therapeutics in the second quarter valued at approximately $12,668,000. Armistice Capital LLC lifted its holdings in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company's stock valued at $41,132,000 after acquiring an additional 528,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Voyager Therapeutics by 3.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company's stock valued at $9,702,000 after acquiring an additional 37,144 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Voyager Therapeutics by 2.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company's stock valued at $925,000 after acquiring an additional 2,030 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.